Department of Neurology, University Hospital Basel, Basel, Switzerland.
Neurology. 2011 Aug 30;77(9):888-95. doi: 10.1212/WNL.0b013e31822c9135. Epub 2011 Aug 17.
To examine whether prior statin use affects outcome and intracranial hemorrhage (ICH) rates in stroke patients receiving IV thrombolysis (IVT).
In a pooled observational study of 11 IVT databases, we compared outcomes between statin users and nonusers. Outcome measures were excellent 3-month outcome (modified Rankin scale 0-1) and ICH in 3 categories. We distinguished all ICHs (ICH(all)), symptomatic ICH based on the criteria of the ECASS-II trial (SICH(ECASS-II)), and symptomatic ICH based on the criteria of the National Institute of Neurological Disorders and Stroke (NINDS) trial (SICH(NINDS)). Unadjusted and adjusted odds ratios (OR) with 95% confidence intervals were calculated.
Among 4,012 IVT-treated patients, 918 (22.9%) were statin users. They were older, more often male, and more frequently had hypertension, hypercholesterolemia, diabetes, coronary heart disease, and concomitant antithrombotic use compared with nonusers. Fewer statin users (35.5%) than nonusers (39.7%) reached an excellent 3-month outcome (OR(unadjusted) 0.84 [0.72-0.98], p = 0.02). After adjustment for age, gender, blood pressure, time to thrombolysis, and stroke severity, the association was no longer significant (0.89 [0.74-1.06], p = 0.20). ICH occurred by trend more often in statin users (ICH(all) 20.1% vs 17.4%; SICH(NINDS) 9.2% vs 7.5%; SICH(ECASS-II) 6.9% vs 5.1%). This difference was statistically significant only for SICH(ECASS-II) (OR = 1.38 [1.02-1.87]). After adjustment for age, gender, blood pressure, use of antithrombotics, and stroke severity, the OR(adjusted) for each category of ICH (ICH(all) 1.15 [0.93-1.41]; SICH(ECASS-II) 1.32 [0.94-1.85]; SICH(NINDS) 1.16 [0.87-1.56]) showed no difference between statin users and nonusers.
In stroke patients receiving IVT, prior statin use was neither an independent predictor of functional outcome nor ICH. It may be considered as an indicator of baseline characteristics that are associated with a less favorable course.
探讨接受静脉溶栓(IVT)治疗的脑卒中患者中,他汀类药物的使用是否会影响其预后和颅内出血(ICH)发生率。
在 11 项 IVT 数据库的汇总观察性研究中,我们比较了他汀类药物使用者和非使用者的结局。结局指标为 3 个月时的优良结局(改良 Rankin 量表 0-1 分)和 3 类颅内出血。我们区分了所有颅内出血(ICH(all))、基于 ECASS-II 试验标准的症状性颅内出血(SICH(ECASS-II))和基于国立神经病学与卒中研究院(NINDS)试验标准的症状性颅内出血(SICH(NINDS))。计算了未经调整和调整后的比值比(OR)及其 95%置信区间。
在接受 IVT 治疗的 4012 例患者中,918 例(22.9%)为他汀类药物使用者。与非使用者相比,他们年龄更大,男性更多,且高血压、高胆固醇血症、糖尿病、冠心病和同时使用抗血栓药物的比例更高。与非使用者相比,更少的他汀类药物使用者(35.5%)达到了 3 个月时的优良结局(未调整 OR 0.84 [0.72-0.98],p=0.02)。调整年龄、性别、血压、溶栓时间和卒中严重程度后,该关联不再显著(0.89 [0.74-1.06],p=0.20)。他汀类药物使用者颅内出血的发生率呈趋势性升高(ICH(all)20.1%比 17.4%;SICH(NINDS)9.2%比 7.5%;SICH(ECASS-II)6.9%比 5.1%)。仅 SICH(ECASS-II)的差异具有统计学意义(OR=1.38 [1.02-1.87])。调整年龄、性别、血压、抗血栓药物使用和卒中严重程度后,各颅内出血类别(ICH(all)1.15 [0.93-1.41];SICH(ECASS-II)1.32 [0.94-1.85];SICH(NINDS)1.16 [0.87-1.56])的调整后 OR 并无他汀类药物使用者与非使用者之间的差异。
在接受 IVT 治疗的脑卒中患者中,既往他汀类药物的使用既不是功能结局的独立预测因素,也不是颅内出血的独立预测因素。它可能是与预后较差相关的基线特征的一个指标。